ITMCTR2100005253CompletedPhase 4
A randomized, double-blind, placebo-controlled, multicenter clinical study of Jinshuibao in improving the symptoms related to pulmonary and cardiac function of COVID-19 during convalescence
Conditions
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional study
Eligibility Criteria
- Ages
- 18 to 70 (—)
- Sex
- All
Inclusion Criteria
- •1. meet the new coronary virus pneumonia recovery period diagnostic criteria;
- •2. short breath, sweating, dry cough, chest tightness, palpitations, etc., three symptoms, or single symptom visual simulation score method (VAS) >=4;
- •3. the cure discharge is more than 2 weeks;
- •4. aged 18 ~ 70 years old;
- •5. sign the informed consent.
Exclusion Criteria
- •1. other reasons causted short breath, sweating, dry cough, chest tightness, palpitations and other pulmonary heart function;
- •2. Patients with difficult drugs due to basic diseases;
- •3. with severe basic diseases that affect survival, including Uncontrolled has a clinical heart, lung, kidney, digestion, blood disease, neuroplastic disease, immune disease, metabolic disease, malignant tumor, severe malnutrition, etc.;
- •4. allergic body, drugs involved in treatment Allergies;
- •5. pregnancy or lactating women;
- •6. mental state can not be collaborators, suffering from mental illness, no self-control, can not clearly express;
- •7. are participating in other clinical trials;
- •8. according to researchers In case of patients affecting efficacy and safety assessment of incoming complications or poor computes.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Study on the safety of the drug runcaciguat and how well it works when given at the highest dose as tolerated by the individual patient whose kidneys are not working properly and suffering at the same time from a disease of the heart and the blood vessels and high blood sugarTreatment of cardiovascular and renal disease in patients with chronic kidney diseaseMedDRA version: 21.1Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 20.0Level: PTClassification code 10001580Term: AlbuminuriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2019-003297-53-ESBayer AG432
Active, not recruiting
Not Applicable
A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of licarbazepine 750-2500 mg/d combined with risperidone in the treatment of manic episodes of bipolar I disorder over 6 weeksBipolar I disorder, manic and mixed episodesEUCTR2004-000113-18-HUovartis Hungaria Kft.430
Active, not recruiting
Phase 1
Phase 2b dose-ranging study of ALX-0171 in infants and young children hospitalized for RSV lower respiratory tract infectioRSV lower respiratory tract infectionMedDRA version: 20.1Level: PTClassification code 10061603Term: Respiratory syncytial virus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2016-001651-49-SKAblynx NV180
Active, not recruiting
Phase 1
A randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete response with first-line rituximab-chemotherapyDiffuse Large B-Cell LymphomaMedDRA version: 19.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-000498-40-HUovartis Pharma Services AG487
Active, not recruiting
Phase 1
Safety and efficacy study in patients with moderate to severe nail psoriasisModerate to severe nail psoriasisMedDRA version: 18.0Level: PTClassification code 10028703Term: Nail psoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2012-005413-40-BEovartis Pharma Services AG195